Therefore, the inhibition of the TLR4-NF-κB pathway can reduce the synovitis response in RA, and the TLR4-NF-κB pathway can be one of the therapeutic targets for RA synovitis [17]. This evidence concerns the gene TLR4 and rheumatoid arthritis.